CTOs on the Move

Worldwide Clinical Research

www.wwcr-cro.com

 
Worldwide Clinical Research is a Overland Park, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.wwcr-cro.com
  • 10955 Lowell Ave Ste 1010
    Overland Park, KS USA 66210
  • Phone: 913.681.3078

Executives

Name Title Contact Details

Similar Companies

Hysitron

Hysitron, Inc is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eddingpharm Group Co.

Eddingpharm Group Co. is a Carrboro, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aspen Laser

Aspen Laser Systems is redefining pain management and recovery with our high intensity, class IV laser therapy devices. With over 30 years of experience, Aspen Laser delivers quality products and long-lasting results for your patients.

Auxilium

Auxilium is a fully integrated specialty biopharmaceutical company focused on developing and marketing products to predominantly specialist audiences. Auxilium means “assistance” in Latin, and that’s a fitting description for all of our biopharmaceutical development and commercialization efforts. Although we are living in an era of rapid advances in medical technology, many of society’s medical concerns remain unaddressed. Auxilium works to address some of these unmet needs. By doing so, we work in important areas of the pharmaceutical industry that require forward thinking and novel solutions that promote better health and living. Through advancement and expansion, Auxilium is dedicated to providing innovative solutions for underserved diseases that improve health and quality of life.

Vitality Biopharma

Vitality has developed a new class of cannabinoid prodrugs (cannabosides), which enable selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Site-specific delivery could enable potent local therapeutic effects while reducing or avoiding the systemic delivery of THC to the brain. Currently, the psychoactivity of THC limits the dose of cannabinoids that can be used for treatment of pain and inflammation. Studies have shown that the cannabinoid system is a potent mediator of pain relief and inflammation, as studies have shown that cannabinoid drugs can in some cases be far more potent than opiates for pain relief, and far more potent than aspirin or corticosteroids for providing anti-inflammatory effects. For example, cannabinoid drugs have been shown to be nearly 10 times as potent as morphine for neuropathic pain relief. Studies have also shown they can be 20 times as potent as aspirin, and twice as potent as corticosteroids for treating inflammation. But currently, the “elephant in the room” remains, which is that the desired potent effects cannot be achieved when high doses of THC enter the bloodstream and brain. Patients are forced to limit their doses, so targeted administration is critical. Our solution goes to the heart of this issue and offers an alternative means to increase the beneficial dosage, right at the site of disease – where it matters most, and relegates the psychoactive nature of the drug to a manageable side effect.